Amgen Joins Public-Private Program for Personalized Medicine Lung Cancer Approach
Amgen reports that it collaborate with the
Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol. Approximately 500 to 1,000 patients will be screened each year for more than 200 cancer-related genes, and the screenings will inform trial arm selection. Five investigational drugs have been selected for inclusion in the initial trial, including
Source: Amgen